Skip to main content
Erschienen in: Obesity Surgery 6/2017

13.12.2016 | Original Contributions

Effects of Bariatric Surgery on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease

verfasst von: Geraldine J. Ooi, Paul R. Burton, Lisa Doyle, John M. Wentworth, Prithi S. Bhathal, Ken Sikaris, Michael A. Cowley, Stuart K. Roberts, William Kemp, Arul Earnest, Paul E. O’Brien, Wendy A. Brown

Erschienen in: Obesity Surgery | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Nonalcoholic fatty liver disease (NAFLD) affects over 80% of obese patients and is fueled by the metabolic syndrome. Weight loss is strongly advocated as a central treatment for NAFLD and has been shown to induce histological improvement. We aimed to define the patterns of improvement in NAFLD with weight loss and determine target weight goals for NAFLD resolution.

Methods

A prospective study of 84 morbidly obese patients with NAFLD undergoing bariatric surgery was conducted. Intraoperative liver biopsies were taken. Monthly follow-up, including blood tests and measurements, was performed. We monitored improvements in NAFLD by monthly alanine aminotransferase (ALT) and gamma glutamyltransferase (GGT) levels over 1 year.

Results

There was rapid improvement in ALT, particularly in the first 6 months following surgery, with statistically significant reduction in ALT at 2 months (35 vs 27 IU/L, p < 0.001). In multivariate analysis, there were significantly increased odds of ALT normalization after a %TBWL of 10–15% (odds ratio 2.49, p = 0.005). The odds of resolution increased with increasing weight loss. Triglyceride levels (odds ratio 0.59, p = 0.021) and baseline NAFLD activity score (odds ratio 0.28, p < 0.001) were also significantly related to ALT normalization. Improvements in ALT occurred prior to metabolic improvement and well before traditional ideal weight goals were reached.

Conclusion

Improvements in NAFLD occurred rapidly after bariatric surgery and were closely related to weight loss and metabolic factors. A 10–15% reduction in body weight is an appropriate target to achieve substantial improvement in ALT levels.
Trial registration number: Australian Clinical Trials Registry (ACTRN12610000049077).
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterology. 2006;40(Suppl 1):S5–S10. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterology. 2006;40(Suppl 1):S5–S10.
2.
Zurück zum Zitat Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;1(8):Suppl4–8. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;1(8):Suppl4–8.
3.
Zurück zum Zitat Williams KH, Shackel NA, Gorrell MD, et al. Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84–129.CrossRefPubMed Williams KH, Shackel NA, Gorrell MD, et al. Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84–129.CrossRefPubMed
4.
Zurück zum Zitat Lebovics E, Rubin J. Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Diabetes Metab Res Rev. 2011;27:419–24.CrossRefPubMed Lebovics E, Rubin J. Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Diabetes Metab Res Rev. 2011;27:419–24.CrossRefPubMed
5.
Zurück zum Zitat Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2011;(6):Art.No.:CD003619. Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2011;(6):Art.No.:CD003619.
6.
Zurück zum Zitat Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39(6):1647–54.CrossRefPubMed Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39(6):1647–54.CrossRefPubMed
7.
Zurück zum Zitat Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improved nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg. 2005;242:610–20.PubMedPubMedCentral Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improved nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg. 2005;242:610–20.PubMedPubMedCentral
8.
Zurück zum Zitat Pontiroli AE, Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. A systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg. 2011;253:484–7.CrossRefPubMed Pontiroli AE, Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. A systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg. 2011;253:484–7.CrossRefPubMed
9.
Zurück zum Zitat Gulliford MC, Booth HP, Reddy M, et al. Effect of contemporary bariatric surgical procedures on type 2 diabetes remission. Obes Surg: A population-based matched cohort study; 2016. doi:10.1007/s11695-016-2103-6. Gulliford MC, Booth HP, Reddy M, et al. Effect of contemporary bariatric surgical procedures on type 2 diabetes remission. Obes Surg: A population-based matched cohort study; 2016. doi:10.​1007/​s11695-016-2103-6.
10.
Zurück zum Zitat Moretto M, Kupski C, Da Silva VD, et al. Effect of bariatric surgery on liver fibrosis. Obes Surg. 2012;22(7):1044–9.CrossRefPubMed Moretto M, Kupski C, Da Silva VD, et al. Effect of bariatric surgery on liver fibrosis. Obes Surg. 2012;22(7):1044–9.CrossRefPubMed
11.
Zurück zum Zitat Tai CM, Huang CK, Hwang JC, et al. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg. 2012;22(7):1016–21.CrossRefPubMed Tai CM, Huang CK, Hwang JC, et al. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg. 2012;22(7):1016–21.CrossRefPubMed
12.
Zurück zum Zitat Taitano AA, Markow M, Fiana JE, et al. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg. 2014;19(3):429–36.CrossRefPubMed Taitano AA, Markow M, Fiana JE, et al. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg. 2014;19(3):429–36.CrossRefPubMed
13.
Zurück zum Zitat Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg. 2006;16(10):1278–86.CrossRefPubMed Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg. 2006;16(10):1278–86.CrossRefPubMed
14.
Zurück zum Zitat Neuschwander-Tetri BA, Bass NM, Brunt EM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3):913–24.CrossRefPubMedPubMedCentral Neuschwander-Tetri BA, Bass NM, Brunt EM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3):913–24.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469–80.CrossRefPubMed Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469–80.CrossRefPubMed
16.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609.CrossRefPubMed Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609.CrossRefPubMed
18.
Zurück zum Zitat Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.CrossRefPubMed Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.CrossRefPubMed
19.
Zurück zum Zitat Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2010;53(3):810–20.CrossRef Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2010;53(3):810–20.CrossRef
20.
Zurück zum Zitat Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10.24.CrossRefPubMed Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10.24.CrossRefPubMed
21.
Zurück zum Zitat Kim WR, Flamm SL, Di Bisceglie AH, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47(4):1363–70.CrossRefPubMed Kim WR, Flamm SL, Di Bisceglie AH, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47(4):1363–70.CrossRefPubMed
22.
23.
Zurück zum Zitat The Look AHEAD Research Group. The Look AHEAD Study: a description of the lifestyle intervention and the evidence supporting it. Obesity. 2006;14(5):737–52.CrossRefPubMedCentral The Look AHEAD Research Group. The Look AHEAD Study: a description of the lifestyle intervention and the evidence supporting it. Obesity. 2006;14(5):737–52.CrossRefPubMedCentral
24.
Zurück zum Zitat Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors with overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–6.CrossRefPubMedPubMedCentral Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors with overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–6.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Curioni C, Lourenco PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes. 2005;29:1168–74.CrossRef Curioni C, Lourenco PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes. 2005;29:1168–74.CrossRef
26.
Zurück zum Zitat Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal faty by serial imaging. Am J Clin Nutr. 2006;84(2):304–11.PubMed Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal faty by serial imaging. Am J Clin Nutr. 2006;84(2):304–11.PubMed
27.
Zurück zum Zitat Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia. 2008;51(10):1781–9.CrossRefPubMed Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia. 2008;51(10):1781–9.CrossRefPubMed
28.
Zurück zum Zitat Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–62.CrossRefPubMed Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–62.CrossRefPubMed
29.
Zurück zum Zitat Le Roux CW, Aylwin SJB, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243(1):108–14.CrossRefPubMed Le Roux CW, Aylwin SJB, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243(1):108–14.CrossRefPubMed
30.
Zurück zum Zitat Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–78.CrossRefPubMed Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–78.CrossRefPubMed
31.
Zurück zum Zitat Marchesini G, Petta S, Grave R. Diet, weight loss, and liver health in NAFLD: pathophysiology, evidence and practice. Hepatology. 2015; doi:10.1002/hep.28392. Marchesini G, Petta S, Grave R. Diet, weight loss, and liver health in NAFLD: pathophysiology, evidence and practice. Hepatology. 2015; doi:10.​1002/​hep.​28392.
32.
Zurück zum Zitat Wu WC, Wu CY, Wang YJ. Updated thresholds for serum alanine amintransferase level in a large-scale population study composed of 34,346 subjects. Aliment Pharmacol Ther. 2012;36(6):560–8.CrossRefPubMed Wu WC, Wu CY, Wang YJ. Updated thresholds for serum alanine amintransferase level in a large-scale population study composed of 34,346 subjects. Aliment Pharmacol Ther. 2012;36(6):560–8.CrossRefPubMed
33.
Zurück zum Zitat Kariv R, Leshno M, Beth-Or A, et al. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int. 2006;26:445–50.CrossRefPubMed Kariv R, Leshno M, Beth-Or A, et al. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int. 2006;26:445–50.CrossRefPubMed
34.
Zurück zum Zitat Kleiner DE, Berk PD, Hsu JY, et al. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) study. Semin Liver Dis. 2014;34(1):98–107.CrossRefPubMedPubMedCentral Kleiner DE, Berk PD, Hsu JY, et al. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) study. Semin Liver Dis. 2014;34(1):98–107.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy—AASLD Position Paper. Hepatology. 2009;49(3):1017–44.CrossRefPubMed Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy—AASLD Position Paper. Hepatology. 2009;49(3):1017–44.CrossRefPubMed
36.
Zurück zum Zitat Asrani SK. Incorporation of non-invasive measures of liver fibrosis into clinical practice: diagnosis and prognosis. Clin Gastroenterol Hepatol. 2015;13(12):2190–204.CrossRefPubMed Asrani SK. Incorporation of non-invasive measures of liver fibrosis into clinical practice: diagnosis and prognosis. Clin Gastroenterol Hepatol. 2015;13(12):2190–204.CrossRefPubMed
37.
38.
Zurück zum Zitat Machado MV, Cortez-Pinto H. Non-invasive diagnosis of nonalcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58:1007–19.CrossRefPubMed Machado MV, Cortez-Pinto H. Non-invasive diagnosis of nonalcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58:1007–19.CrossRefPubMed
Metadaten
Titel
Effects of Bariatric Surgery on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease
verfasst von
Geraldine J. Ooi
Paul R. Burton
Lisa Doyle
John M. Wentworth
Prithi S. Bhathal
Ken Sikaris
Michael A. Cowley
Stuart K. Roberts
William Kemp
Arul Earnest
Paul E. O’Brien
Wendy A. Brown
Publikationsdatum
13.12.2016
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 6/2017
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-016-2482-8

Weitere Artikel der Ausgabe 6/2017

Obesity Surgery 6/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.